Madrigal Pharmaceuticals MDGL Estimates

NASDAQ MDGL
$546.53 +3.92 (+0.72%)
As of: Sep 4, 2026 · 11:47 AM EDT
Analyst Estimates

Madrigal Pharmaceuticals, Inc. Revenue Estimates

Periods 26
Next Period Q3 26
Consensus 378.84 M

Analysts expect Madrigal Pharmaceuticals, Inc. to report revenue of 378.84 M for Q3 26, against a range of 356.66 M to 401.02 M. The most recent reported quarter, Q2 26, came in at 364.30 M, a 6.6% beat against the 341.84 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 62.20 M103.32 M137.25 M212.80 M287.27 M321.10 M311.34 M364.30 M--------
High Estimate 35.17 M109.38 M122.53 M178.47 M289.97 M329.26 M330.43 M369.59 M401.02 M448.63 M460.99 M532.55 M635.96 M657.13 M696.23 M696.79 M
Low Estimate 29.63 M102.11 M113.73 M152.15 M239.29 M280.25 M286.88 M314.09 M356.66 M407.40 M392.37 M444.25 M564.93 M579.91 M636.39 M637.85 M
Consensus Estimate 32.40 M105.75 M118.13 M165.31 M264.63 M304.76 M308.65 M341.84 M378.84 M428.01 M426.68 M488.40 M600.45 M618.52 M666.31 M667.32 M
Analyst Estimates

Madrigal Pharmaceuticals, Inc. Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q3 26
Consensus -0.95

Analysts expect Madrigal Pharmaceuticals, Inc. to report earnings per share of -0.95 for Q3 26, against a range of -1.02 to -0.88. The most recent reported quarter, Q2 26, came in at -1.99, a 20.7% beat against the -2.51 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -4.92-2.71-3.32-1.90-5.08-2.57-3.25-1.99--------
High Estimate -6.35-3.85-3.74-3.20-2.32-0.87-4.19-2.26-0.88-0.23-0.331.051.172.684.796.62
Low Estimate -7.69-4.35-4.00-3.54-2.52-0.97-4.45-2.76-1.02-0.27-0.390.891.032.284.175.76
Consensus Estimate -7.02-4.10-3.87-3.37-2.42-0.92-4.32-2.51-0.95-0.25-0.360.971.102.484.486.19